Pioneering in
AI-driven
precision medicine
precision medicine
Pioneering in
Helixa uses Artificial Intelligence and Next Generation Sequencing methods to predict the likely effectiveness of FDA-approved drugs with close to 100% accuracy.
HELIXA contributes to human health by using the most advanced genomic technology available. We use genetic information based on clinical outcomes to treat patients with FDA approved drugs which have a high likelihood of success. Our technology is integrated with global medical organizations who can provide the best possible solutions.
Benefits
Diagnosis
Cancer genome analyses for the detection of targetable mutations provides clinicians with evidence based actionable information to empower precision therapy.
Drug Selection
Decisions on drug selection and dose are made by the oncologist, supported by highly accurate data generated by our noise-filtering AI algorithms with near to 100% accuracy.
Prognosis
Prognoses are generated based on the probability of the development of cancer with consideration to the mutations detected by the Helixa AI engine.
Prediction
Probable outcomes for individual patients are made using statistical analyses from ten South Korean hospitals and AI-driven literature data mining.
The Process
1. Sample
We collect and prepare tumour tissue samples. Each sample is 100mm squared at 5 microns thick.
2. Sequence
Sequencing of DNA or RNA fragments is performed using state-of-the-art Sequencing technology.
3. Analyse
We use AI and data mining to discover novel data platforms, genotyping methods, emerging biomarkers, and therapeutic siRNA.
4. Report
A report is generated in approximately four weeks from sample collection and sent to the oncologist treating the patient to guide their final decision.
